Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2783

Sigma-Aldrich

VU0409551

≥98% (HPLC)

Synonym(s):

JNJ 46778212, JNJ-46778212, VU 0409551, [6,7-Dihydro-2-(phenoxymethyl)oxazolo[5,4-c]pyridin-5(4H)-yl](4-fluorophenyl)methanone

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
R$700.00
25 MG
R$2,821.00

R$700.00

Estimated to ship onApril 11, 2025

Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
R$700.00
25 MG
R$2,821.00

About This Item

Empirical Formula (Hill Notation):
C20H17FN2O3
CAS Number:
1363281-27-9
Molecular Weight:
352.36
MDL number:
MFCD29047143
UNSPSC Code:
12352200
NACRES:
NA.77

R$700.00

Estimated to ship onApril 11, 2025

Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(N1CCC2=C(C1)OC(COC3=CC=CC=C3)=N2)C4=CC=C(C=C4)F

InChI key

QUZLMKNNIUSREV-UHFFFAOYSA-N

Biochem/physiol Actions

VU0409551 (JNJ-46778212) is an orally available, potent and selective biased metabotropic glutamate receptor subtype 5 positive allosteric modulator (mGlu5 PAM). VU0409551 (JNJ-46778212) selectively potentiates mGlu5 coupling to Gaq-mediated signaling without modulation of NMDAR currents in hippocampal neurons. VU0409551 exhibits potent antipsychotic-like and cognition enhancing activity in animal models.
orally available, potent and selective biased mGlu5 PAM

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000358174
0000349351
0000349351
0000358174
0000243103

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Darrick T Balu et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 41(8), 2052-2061 (2016-01-08)
There is substantial evidence that NMDA receptor (NMDAR) hypofunction contributes to the pathophysiology of schizophrenia (SCZ). A recent large-scale genome-wide association study identified serine racemase (SR), the enzyme that produces the NMDAR co-agonist D-serine, as a risk gene for SCZ.
Shane D Hellyer et al.
Journal of neurochemistry, 151(3), 301-315 (2019-08-04)
Allosteric modulators of metabotropic glutamate receptor 5 (mGlu5 ) are a promising therapeutic strategy for a number of neurological disorders. Multiple mGlu5 -positive allosteric modulator (PAM) chemotypes have been discovered that act as either pure PAMs or as PAM-agonists in
Jerri M Rook et al.
Neuron, 86(4), 1029-1040 (2015-05-06)
Schizophrenia is associated with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling. The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely associated signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathology

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service